CVS Shares Dip on Strong Volume Surge to 65th Rank as Earnings Highlight Growth and Legal Challenges

On July 31, 2025, CVS Health (CVS) closed with a 0.32% decline, trading at a volume of $1.75 billion, a 82.97% surge from the prior day, ranking 65th in market activity. The stock’s performance followed the release of its Q2 2025 earnings report, which highlighted a 8.4% year-over-year revenue increase to $98.9 billion. Adjusted EPS of $1.81 exceeded expectations, though GAAP diluted EPS fell to $0.80 amid litigation charges. The company revised its full-year guidance, narrowing GAAP EPS to $3.84–$3.94 and raising adjusted EPS to $6.30–$6.40, reflecting improved performance in Health Care Benefits and Pharmacy & Consumer Wellness segments, partially offset by weaker Health Services results.

CVS’s operational updates underscored strategic moves, including the acquisition of Rite Aid’s prescription files and stores in select states and Aetna’s advancements in care navigation. CEO David Joyner emphasized the company’s focus on simplifying healthcare access and affordability, with a $20 billion investment over the next decade to enhance interoperability and member outcomes. However, litigation costs from legacy business practices, including a $542 million charge in Q2 related to False Claims Act penalties, weighed on GAAP results. The Health Services segment saw a 17.8% drop in adjusted operating income, driven by pharmacy client price pressures and higher medical benefit ratios.

The stock’s muted response to earnings highlights investor caution amid sector-wide challenges, including Medicare Advantage cost trends and regulatory scrutiny of pharmacy benefit managers. Despite raising 2025 revenue guidance to $139 billion, the company acknowledged a “multiyear recovery” path for margins, with CFO Brian Newman noting ongoing trade-offs between growth and profitability. The revised MLR of 91% for the full year aligns with industry peers, signaling cautious optimism about cost management in a high-inflation environment.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day has delivered a 166.71% return from 2022 to July 30, 2025, outperforming the benchmark by 137.53%. This performance reflects the resilience of high-liquidity stocks in volatile markets, with momentum and investor sentiment driving short-term gains. The approach underscores the potential of liquidity-focused strategies to capitalize on market dynamics, particularly in sectors like healthcare where regulatory and operational shifts create trading opportunities.